A Phase III clinical trial found that nicotinamide riboside, an NAD-boosting supplement, did not slow Parkinson’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results